Letter to the editor

The first Japanese case of familial porphyria cutanea tarda diagnosed by a *UROD* mutation

Dear Editor,

Porphyria cutanea tarda (PCT) is a disorder of porphyrin metabolism associated with cutaneous photosensitivity that usually presents with blistering on the face and dorsal hands and signs of liver damage. The disease is caused by a deficiency in uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme synthesis pathway. Three clinically similar forms of PCT can be distinguished: sporadic (type I or S-PCT), familial (type II or F-PCT), and type III [1]. F-PCT is an autosomal dominant disorder with low penetrance that is characterized by a heterozygous *UROD* mutation. Most PCT patients have the sporadic type, which is not associated with mutations in *UROD*. In this paper we report the first Japanese case of F-PCT with a previously unreported pathogenic *UROD* mutation.

A 26-year-old Japanese fisherman presented with a 4-year-history of exanthema after sun exposure. He was diagnosed with liver damage 2 months previously. His alcohol intake was more than 28 g daily for more than 9 years. His family history of PCT was negative. Physical examination revealed multiple fine pitted scars across the face (Fig. 1A). Diffuse erythema was noted, and was most prominent on the upper eyelids. Variously sized erythematous patches with crusting and pigmentation were seen on the dorsal hands (Fig. 1B). Blood examination showed elevated levels of AST (55 IU/L; normal, 10–40), ALT (83; normal, 5–40), and γ-GTP (96 IU/L; normal, <70). Serum hepatitis B antigen and anti-hepatitis C antibody were negative. Porphyrin tests demonstrated increased urine uroporphyrin levels (604 mg/dL·creatinine; normal, <36), while urine coproporphyrin, erythrocyte protoporphyrin, and erythrocyte coproporphyrin levels were within normal limits. Based on these clinical findings, a diagnosis of PCT was made. After obtaining written informed consent and following the Declaration of Helsinki, we performed mutational analysis using genomic DNA extracted from peripheral blood leukocytes of the proband, his elder brother, and his parents. Direct sequencing demonstrated a heterozygous single nucleotide change at the intron 6 / exon 7 border of *UROD*, designated as c.673-2A>C (Fig. 2A). In the proband, while his elder brother and parents do not have the nucleotide change. This nucleotide change was located at the splicing acceptor site of intron 6, suggesting it would cause exon skipping. To confirm this, we determined the primary structure of *UROD* mRNA prepared from the proband's leukocytes. Gel electrophoresis showed that reverse transcriptase

(RT)-PCR products of the proband demonstrated a shorter band (Fig. 2B, arrow) as well as a band with the expected size (Fig. 2B, arrowhead). Direct sequencing of the shorter band revealed the whole deletion of exon 7 (Fig. 2C), confirming the skipping of exon 7. This deletion mutation was predicted to result in an in-frame 46-amino-acid deletion, designated as p.A213_M258del. We then performed immunoblotting to identify the mutant UROD protein with a predicted size of 35 kDa. We detected the wild-type UROD protein bands at approximately 40 kDa in all the samples (Fig. 2D, arrowhead). The expression level of the proband's UROD was approximately half that of control, as determined by densitometry (data not shown). However, no band corresponding to the 35-kDa mutant UROD was detected (Fig. 2D). Instead, a single band at 30 kDa was observed non-specifically in both of the proband and control in all repeated blottings (Fig. 2D, arrow). The aberrant UROD protein may be unstable and be degraded at the protein level.

PCT is the most common type of porphyria, and is caused by decreased UROD activity. F-PCT occurs in 20–30% of PCT patients in Western countries and has the same symptoms as S-PCT [2]. A literature search using ICHUSHI in Japan and PubMed identified 355 prior cases of PCT in Japan. Unexpectedly, only four PCT cases with positive family histories have been reported, and none have been genetically analyzed [2,3]. F-PCT is therefore extremely rare in Japan compared with Western populations, but the reason for this remains unclear. We could not find F-PCT cases in Korea and China, suggesting a low incidence of F-PCT in East Asians [4]. So far, the splice-site mutation demonstrated here has been reported in neither PubMed nor Human Genome Mutation Database® Professional, suggesting the mutation is a novel one. All the unaffected family members consisted of his elder brother and parents do not have the mutation, suggesting that this is a *de novo* *UROD* mutation.

In F-PCT, heterozygous mutations in *UROD* reduce UROD activity to about 50% in all tissues, predisposing carriers to clinical manifestations. Immunoblotting showed a 50% reduction of the wild-type UROD protein level in the proband (Fig. 2D). F-PCT also requires precipitating factors such as excessive alcohol intake, drug use, and HCV infection [5]. In our patient, alcohol consumption beginning at an early age may have precipitated the development of F-PCT. Sun protection whenever possible and abstinence effectively improved the patient's photosensitivity and liver damage, respectively.

In conclusion, we describe the first Japanese case of F-PCT with a novel splice-site *UROD* mutation. Efforts to detect *UROD* mutation heterozygotes in PCT families are required to prevent these individuals from developing PCT by encouraging them to avoid known precipitating factors.

Fig. 1. Clinical Findings. (A) Physical examination revealed multiple fine pitted scars across the face. Diffuse erythema was noted, and was most prominent on the upper eyelids. (B) Variously sized erythematous patches with crusting and pigmentation were seen on the dorsal hands.

Fig. 2. Molecular analyses. (A) Direct sequencing demonstrated a heterozygous single nucleotide change at the intron 6 / exon 7 border of *UROD*, designated as c.673-2 A > C. (B) RT-PCR analysis of *UROD* mRNA from the proband. Gel electrophoresis showed that RT-PCR products of the proband demonstrated a shorter band (arrow) as well as a band with the expected size (arrowhead). M, molecular marker; C, control; P, proband. The primer sequences to amplify the specific *UROD* cDNA are as follows; 5′−CCCAGAGCCATTAAGAGAAG-3′ (forward) and 5′-AGCCCAACCACCTCATAGCC-3′ (reverse). (C) Direct sequencing of the shorter band revealed the whole deletion of exon 7, confirming the skipping of exon 7. (D) Immunoblotting using antibodies against UROD (Bioworld Technology, BS7604) (upper panel) and β-actin (lower panel). C, control; P, proband. These blots are representative of three independent experiments.

References

[1] M. Méndez, M.V. Rossetti, S. Gómez-Abecia, M.J. Moran-Jimenez, V. Parera, A. Batlle, R. Enriquez de Salamanca, Molecular analysis of the UROD gene in 17 Argentinean patients with familial porphyria cutanea tarda: characterization of four novel mutations, Mol. Genet. Metab. 105 (2012) 629–633.

[2] S. Adachi, J. Amano, H. Ito, T. Yajima, T. Shirai, Y. Miyahara, F. Marumo, M. Hiroe, Porphyria cutanea tarda with constrictive pericardiis in a family, Heart J. 88 (1997) 749–753.

[3] M. Kondo, Y. Yano, G. Urata, Porphyrias in Japan: Compilation of all cases reported through 2010, ALA-Porphyrin Sci. 2 (2012) 73–82 (in Japanese).

[4] B.P. Khoo, Y.K. Tay, Porphyria cutanea tarda, Singapore Med. J. 41 (2000) 292–294.

[5] N.G. Egger, D.E. Goeger, D.A. Payne, E.P. Miskovsky, S.A. Weinman, K.E. Anderson, Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency, Dig. Dis. Sci. 47 (2002) 419–426.

Akinobu Matsui, Eijiro Akasaka, Daiki Rokunohe, Yasushi Matsuzaki, Daisuke Sawamura, Hajime Nakano[*]
Department of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

[*] Corresponding author at: Department of Dermatology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.
E-mail address: dnarna2016@yahoo.co.jp (H. Nakano).

Letter to the Editor

Dysbiosis of oral microbiota in palmoplantar pustulosis patients

Palmoplantar pustulosis (PPP), a chronic inflammatory skin disease, is characterized by sterile pustular eruptions and erythematous scaling on the palms and soles [1]. Nearly 10% of patients suffer from joint manifestation, pustulotic arthro-osteosis (PAO) [1]. Both skin and joint symptoms are triggered or worsened by focal infections including tonsillitis and dental infection [1]. Recently, we retrospectively evaluated the efficacy of dental infection control and tonsillectomy on the clinical outcomes of 85 PPP patients, and demonstrated that oral focal infections were closely associated with disease severity [2]. These findings led us to hypothesize that changes in oral microbioata based on focal infections may correlate to disease severity and clinical characteristics of PPP. Here, oral microbiota of PPP patients and healthy controls were comparatively analyzed by next generation sequencing (NGS) of the V3-V4 region of the bacterial 16S ribosomal RNA (rRNA) gene.

We surveyed the microbiota of unstimulated saliva collected from 12 PPP patients (pts) and 10 healthy controls (HCs), who were all Japanese and residents in central Japan. General and clinical characteristics of the subjects are shown in Table 1. Prevalence of major worsening factors for PPP, smoking habit and periodontitis were higher in the pts. The methods of sequencing and statistical analysis are described in Supplementary materials and methods. First, we compared the bacterial community composition of the pts and HCs using UniFrac, a phylogenic tree-based measurement ranging from 0 (identical communities) to 1 (completely different communities). The UniFrac distance between HCs-pts (0.37) was significantly higher than that between HCs-HCs (0.31) and between pts-pts (0.31) ($P < 0.05$), indicating a significant difference in oral microbiota between pts and HCs (Fig. 1B). According to the principle coordinate analysis (PCoA) plot based on UniFrac distances, a clearly different distribution between pts and HCs (Fig. 1A) was shown. These results indicated that oral microbiota of the pts significantly differed from that of the HCs, and suggested oral dysbiosis in PPP patients. Second, we evaluated the difference in

the oral microbiota among the pts regarding the following characteristics: joint manifestation (PAO) (n = 7), periodontitis (n = 6), smoking habit (n = 9) and higher disease severity according to Palmoplantar Pustulosis Area and Severity Index (PPPASI) score (n = 6). From these results, subjects in the pts with these characteristics showed a different oral bacterial community (Fig. 1C). Third, we analyzed the relative bacterial abundance in all subjects in the pts, subjects in the pts with PAO, periodontitis, smoking habit and higher PPPASI score, and subjects without these characteristics. Six major phyla: Actinobactera, Bacteroidetes, Firmicutes, Fusobacteria, Proteobacteria and TM7, and 13 genera selected as the majority of 16S readings were analyzed (Fig. 1D and Table S1). Results of comparison between the pts and HCs demonstrated that the pts had less Proteobacteria (pts = 24%, HCs = 37%, $P < 0.05$) at the phyla level, and less *Haemophilus* (pts = 10%, HCs = 17%, $P < 0.05$) and more Prevotella (pts = 17%, HCs = 10%, $P < 0.05$) at the genus level. Interestingly, all of these features were shared only in subjects in the pts with PAO (Proteobacteria: pts with PAO = 21%, HCs = 37%; *Haemophilus*: pts with PAO = 8%, HCs = 17%; Prevotella: pts with PAO = 20%, HCs = 10%; $P < 0.05$). According to previous oral microbiome studies in other autoinflammatory diseases by two Japanese groups, these changes in bacterial abundance (less Proteobacteria, less *Haemophilus* and more Prevotella) were also observed. The

Table 1

Characteristics of patients with Palmoplantar Pustulosis (pts) and healthy controls (HCs).

	pts (n = 12), n(%)	HCs (n = 10), n(%)
Sex		
Female	8 (67%)	3 (30%)
Male	4 (33%)	7 (70%)
Age (yrs), mean ± SD	53.7 ± 14.6	29.5 ± 2.87
Smoking habit	9 (75%)	3 (30%)
Periodontitis [a]	6 (50%)	0 (0%)
Tonsillitis	0 (0%)	0 (0%)
Joint manifestation	7 (58%)	NA [b]
PPPASI [c]		
Range	0.4–19.2	NA [b]
Low score group (range)	6 (0.4–4.9)	NA [b]
High score group (range)	6 (5.4–19.2)	NA [b]

[a] Periodontitis was diagnosed using CDC-AAP.

[b] NA: not applicable.

[c] PPPASI : Palmoplantar Pustulosis Area and Severity Index.